The information on this site is intended for US healthcare professionals and clinical staff only.
Demonstrated efficacy in single-agent and combination studies
Select an indication to view efficacy or explore ZYDELIG’s mechanism of action
Relapsed follicular lymphoma (FL) in patients who have received at least two prior systemic therapies
Relapsed chronic lymphocytic leukemia (CLL) in combination with rituximab in patients forwhom rituximab alone would be considered appropriate therapy due to other comorbidities
Relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two priorsystemic therapies
ZYDELIG is the first oral PI3Kδ inhibitor approved in both relapsed/refractory follicular lymphoma and relapsed CLL
FL and SLL are approved based on overall response rate. Improvement in patient survival or disease-related symptoms has not been established. Continued approval for these indications may be contingent upon verification of clinical benefit in confirmatory trials.
ZYDELIG is not indicated or recommended for first-line treatment of any patient or in combination with bendamustine and/or rituximab for the treatment of FL.
PI3Kδ=phosphatidylinositol 3-kinase delta.